Targeted Delivery of siRNA into Breast Cancer Cells via Phage Fusion Proteins
详细信息 查看全文
- 作者：Deepa Bedi ; James W. Gillespie ; Vasily A. Petrenko ; Jr. ; Andreas Ebner ; Michael Leitner ; Peter Hinterdorfer ; Valery A. Petrenko
- 刊名：Molecular Pharmaceutics
- 出版年：2013
- 出版时间：February 4, 2013
- 年：2013
- 卷：10
- 期：2
- 页码：551-559
- 全文大小：492K
- 年卷期：v.10,no.2(February 4, 2013)
- ISSN：1543-8392
文摘
Nucleic acids, including antisense oligonucleotides, small interfering RNA (siRNA), aptamers, and rybozymes, emerged as versatile therapeutics due to their ability to interfere in a well-planned manner with the flow of genetic information from DNA to protein. However, a systemic use of NAs is hindered by their instability in physiological liquids and inability of intracellular accumulation in the site of action. We first evaluated the potential of cancer specific phage fusion proteins as targeting ligands that provide encapsulation, protection, and navigation of siRNA to the target cell. The tumor-specific proteins were isolated from phages that were affinity selected from a landscape phage library against target breast cancer cells. It was found that fusion phage coat protein fpVIII displaying cancer-targeting peptides can effectively encapsulate siRNAs and deliver them into the cells leading to specific silencing of the model gene GAPDH. Complexes of siRNA and phage protein form nanoparticles (nanophages), which were characterized by atomic force microscopy and ELISA, and their stability was demonstrated by resistance of encapsulated siRNA to degradation by serum nucleases. The phage protein/siRNA complexes can make a new type of highly selective, stable, active, and physiologically acceptable cancer nanomedicine.